Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares.

Kewei Chen | Napatkamon Ayutyanont | Jessica B S Langbaum | Adam S Fleisher | Cole Reschke | Wendy Lee | Xiaofen Liu | Gene E Alexander | Dan Bandy | Richard J Caselli | Eric M Reiman
NeuroImage | 2012

We previously introduced a voxel-based, multi-modal application of the partial least square algorithm (MMPLS) to characterize the linkage between patterns in a person's complementary complex datasets without the need to correct for multiple regional comparisons. Here we used it to demonstrate a strong correlation between MMPLS scores to characterize the linkage between the covarying patterns of fluorodeoxyglucose positron emission tomography (FDG PET) measurements of regional glucose metabolism and magnetic resonance imaging (MRI) measurements of regional gray matter associated with apolipoprotein E (APOE) ε4 gene dose (i.e., three levels of genetic risk for late-onset Alzheimer's disease (AD)) in cognitively normal, late-middle-aged persons. Coregistered and spatially normalized FDG PET and MRI images from 70% of the subjects (27 ε4 homozygotes, 36 ε4 heterozygotes and 67 ε4 non-carriers) were used in a hypothesis-generating MMPLS analysis to characterize the covarying pattern of regional gray matter volume and cerebral glucose metabolism most strongly correlated with APOE-ε4 gene dose. Coregistered and spatially normalized FDG PET and MRI images from the remaining 30% of the subjects were used in a hypothesis-testing MMPLS analysis to generate FDG PET-MRI gray matter MMPLS scores blind to their APOE genotype and characterize their relationship to APOE-ε4 gene dose. The hypothesis-generating analysis revealed covarying regional gray matter volume and cerebral glucose metabolism patterns that resembled those in traditional univariate analyses of AD and APOE-ε4 gene dose and PET-MRI scores that were strongly correlated with APOE-ε4 gene dose (p<1 × 10(-16)). The hypothesis-testing analysis results showed strong correlations between FDG PET-MRI gray matter scores and APOE-ε4 gene dose (p = 8.7 × 10(-4)). Our findings support the possibility of using the MMPLS to analyze complementary datasets from the same person in the presymptomatic detection and tracking of AD.

Pubmed ID: 22348880

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581-11
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-07S1
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-08
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-07
  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581
  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581-10
  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581-12
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-04S1
  • Agency: NIA NIH HHS, United States
    Id: R01AG031581
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-03
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-02
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-06
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-05S1
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-06
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-11
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-10S1
  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581-14
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-08S2
  • Agency: NIA NIH HHS, United States
    Id: P30AG19610
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-04
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-07
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-08
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-10
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-02
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-08S1
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-09
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-03
  • Agency: NIMH NIH HHS, United States
    Id: R01MH57899
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-12
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-05
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-09
  • Agency: NIA NIH HHS, United States
    Id: R01 AG031581-13
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-01
  • Agency: NIA NIH HHS, United States
    Id: P30 AG019610-05
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH057899-04

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SPM (tool)

RRID:SCR_007037

Software package for analysis of brain imaging data sequences. Sequences can be a series of images from different cohorts, or time-series from same subject. Current release is designed for analysis of fMRI, PET, SPECT, EEG and MEG.

View all literature mentions